^
Association details:
Evidence:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer

Excerpt:
Unresectable locally advanced or metastatic histologically proven HER2+ gastroesophageal junction (GEJ) or gastric cancer. Gastric Cancer Expansion Phase will include only gastric cancer patients with 3+ HER2 positivity...Have received prior treatment with trastuzumab.
Trial ID:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

BIOMARKER-GUIDED ENRICHMENT OF THE ANTITUMOR ACTIVITY OF MARGETUXIMAB (M) PLUS PEMBROLIZUMAB (P) IN PATIENTS WITH ADVANCED HER2+ GASTRIC ADENOCARCINOMA (GEA)

Published date:
10/21/2018
Excerpt:
The presence of ERBB2 amplification by ctDNA and tumor PD-L1 expression by IHC were both associated with increased probability of OR: 33.3% v. 10.5% (p = 0.0948) and 43.8% v. 16.7% (p = 0.0769), respectively. ORR was 5 of 8 (62.5%) in ERBB2 amplified/PD-L1+ pts. In pts with activating HER2 mutations DCR was 11/15 (73%), indicating ADCC.
DOI:
10.1093/annonc/mdy282
Trial ID: